SSA
SYRE icon

Schonfeld Strategic Advisors’s Spyre Therapeutics SYRE Stock Holding History

Schonfeld Strategic Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-81,474
Closed -$1.37M – 2568
2025
Q3 		$1.37M Buy
+81,474
New +$1.33M 0.01% 1228
2024
Q4 		– Sell
-46,072
Closed -$1.35M – 2368
2024
Q3 		$1.35M Sell
46,072
-32,428
-41% -$903K 0.01% 1046
2024
Q2 		$1.85M Buy
78,500
+43,000
+121% +$1.45M 0.01% 940
2024
Q1 		$1.35M Buy
+35,500
New +$1.03M 0.01% 1118
2022
Q3 		– Sell
-404
Closed -$5K – 3154
2022
Q2 		$5K Buy
+404
New +$14.2K ﹤0.01% 2324

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Schonfeld Strategic Advisors's SYRE Position: Q4 2025 in Review

Schonfeld Strategic Advisors sold out of Spyre Therapeutics (SYRE) in Q4 2025, closing a stake of 81,474 shares — an estimated $1.37M sold.

Schonfeld Strategic Advisors first reported a position in SYRE in Q2 2022 and held it in 5 quarters. The position peaked at $1.85M in Q2 2024. 153 funds tracked by Wall St. Rank hold SYRE as of Q4 2025.

  • Schonfeld Strategic Advisors reported no remaining Spyre Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 81,474 Spyre Therapeutics shares in Q4 2025, an estimated $1.37M.
  • Schonfeld Strategic Advisors first reported a position in Spyre Therapeutics in Q2 2022 and held it in 5 quarters.
  • Schonfeld Strategic Advisors's Spyre Therapeutics position peaked at $1.85M in Q2 2024.
  • 153 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.